From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
Tumor buster-where will the CAR-T cell therapy 'missile'go?
Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …
technology represents a significant breakthrough in personalized immunotherapy for human …
Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia
R Chiesa, C Georgiadis, F Syed, H Zhan… - … England Journal of …, 2023 - Mass Medical Soc
Background Cytidine deamination that is guided by clustered regularly interspaced short
palindromic repeats (CRISPR) can mediate a highly precise conversion of one nucleotide …
palindromic repeats (CRISPR) can mediate a highly precise conversion of one nucleotide …
Base-editing mutagenesis maps alleles to tune human T cell functions
CRISPR-enabled screening is a powerful tool for the discovery of genes that control T cell
function and has nominated candidate targets for immunotherapies,,,,–. However, new …
function and has nominated candidate targets for immunotherapies,,,,–. However, new …
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
Y Tan, L Shan, L Zhao, B Deng, Z Ling, Y Zhang… - Journal of Hematology & …, 2023 - Springer
Background Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed
feasibility and early efficacy in patients with refractory or relapsed T-cell acute lymphoblastic …
feasibility and early efficacy in patients with refractory or relapsed T-cell acute lymphoblastic …
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
T-cell malignancies are associated with frequent relapse and high morbidity, which is partly
due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells …
due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells …
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
Background Multiple genetic modifications may be required to develop potent off-the-shelf
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …
A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment
X Yang, B Zhang - Functional & Integrative Genomics, 2023 - Springer
Cancer is one of the leading causes of death worldwide and it has the trend of increase
incidence. However, in the past decades, as quickly developed new technologies and …
incidence. However, in the past decades, as quickly developed new technologies and …
CRISPR nuclease off-target activity and mitigation strategies
B Wienert, MK Cromer - Frontiers in Genome Editing, 2022 - frontiersin.org
The discovery of CRISPR has allowed site-specific genomic modification to become a reality
and this technology is now being applied in a number of human clinical trials. While this …
and this technology is now being applied in a number of human clinical trials. While this …
CAR T-cell immunotherapy treating T-ALL: Challenges and opportunities
A Ren, X Tong, N Xu, T Zhang, F Zhou, H Zhu - Vaccines, 2023 - mdpi.com
T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically
aggressive hematological malignancy with high rates of disease relapse and a poor …
aggressive hematological malignancy with high rates of disease relapse and a poor …